Press Releases

Fontem Ventures supports claims from the first cochrane review on EVPS

29.01.15

Britain’s leading EVP (electronic vaping product) producer, Fontem Ventures, welcomes the first study by the Cochrane review,

LONDON, December 17 2014 – Britain’s leading EVP (electronic vaping product) producer, Fontem Ventures, welcomes the first study by the Cochrane review, which demonstrates the positive impact EVPs can have on smoking reduction or cessation for regular tobacco users.

Professor Peter Hajek, a review author from Queen Mary University of London, explained that although the number of trials were small, the results were certainly encouraging. The study shows that 9% of smokers who use EVPs were able to stop smoking for up to a year, compared to 4% of smokers who used non-nicotine devices. Additionally, 38% of EVP users managed to halve the number of traditional cigarettes they smoked, compared to 28% of those users who used a placebo device.

Marc Michelsen, Director of Communications and Public Affairs at Fontem Ventures said: “Fontem Ventures welcomes this latest contribution to our understanding of the impact of EVPs on the use of traditional tobacco products.  Our consumer research shows many and varied reasons why smokers choose EVPs – and that does include, in some cases, a desire to reduce or even completely stop their smoking habit. .

“We agree with the study’s review authors that much more research needs to be undertaken to study the long-term impact of EVPs. Nevertheless, EVPs offer a real alternative to smoking tobacco for those wishing to enjoy nicotine in a way that better suits their life-style today. Moreover, there is a growing consensus among respected organisations and campaigners in the public health field, including Action on Smoking and Health (ASH), that EVPs as an alternative to tobacco could deliver a significant public health benefit.”

ASH in a statement has also welcomed the latest results from the Cochrane review.

blu was founded in the USA in 2009 and is one of the original e-cigarette brands. It was acquired by Fontem Ventures in 2015. As one of the world’s most recognizable vape brands, blu offers adult smokers’ choice through high-quality e-vapour products and e-liquids.

Nerudia was established in 2013 and became part of Imperial Brands in 2017. It is the home of innovation and technology R&D for Next Generation Products (NGP) which includes e-vapour, heated tobacco and oral nicotine delivery. Nerudia is dedicated to creating a world where smokers have choice.

Fontem Ventures is a subsidiary of Imperial Brands PLC, a global consumer organisation and the fourth largest international tobacco company in the world, operating across 120 markets.

[contact-form-7 404 "Not Found"]